Synlogic, Inc. (SYBX) |
| 0.67 0 (0%) 07-27 16:00 |
| Open: | 0.711 |
| High: | 0.711 |
| Low: | 0.67 |
| Volume: | 4,000 |
| Market Cap: | 8(M) |
| PE Ratio: | -11.17 |
| Exchange: | Other OTC |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 0.88 |
| Resistance 1: | 0.75 |
| Pivot price: | 0.71 |
| Support 1: | 0.66 |
| Support 2: | 0.60 |
| 52w High: | 1.87 |
| 52w Low: | 0.54 |
Synlogic, Inc. does not have significant operations. It was previously engaged in the discovery and development of synthetic biotics to treat metabolic diseases. Synlogic, Inc. is based in Winchester, Massachusetts.
Financials
| EPS | -0.060 |
| Book Value | 1.070 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -14.5 |
| Return on Equity (ttm) | -5.0 |
Company news
Sat, 25 Jul 2026
Synlogic, Inc. Revenue Breakdown – OTC:SYBX - TradingView
Sat, 10 Feb 2024
Synlogic Announces Plan to Cease Operations and Reduce Its Workforce by More Than 90% - SynBioBeta
Tue, 19 Sep 2023
Synlogic Announces CEO Aoife Brennan Named to PharmaVoice 100 - GlobeNewswire
Thu, 11 Aug 2022
Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks - PR Newswire
Mon, 14 Sep 2020
Synlogic Appoints David Hava, Ph.D., as Chief Scientific Officer - PR Newswire
Fri, 31 Jul 2020
Synlogic Promotes Antoine Awad to COO - citybiz
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
